Sean A. McCarthy, D. Phil.
Principal executive officer pay for Sean A. McCarthy, D. Phil., by year and company, from pay-versus-performance disclosure. Every figure links to its source on the company page.
CytomX Therapeutics, Inc. (CTMX) FY2022–FY2025
Aligned: paid up as stock roseCAP $671,919→$10,636,158 while $100 invested went $36.95→$266.25
| Fiscal year | SCT total | Comp actually paid |
|---|---|---|
| FY2022 | $3.0M | $671,919 |
| FY2023 | $2.6M | $519,365 |
| FY2024 | $1.8M | $1.1M |
| FY2025 | $4.7M | $10.6M |
The company's "$100 invested" index ran $36.95 at FY2022 → $266.25 by FY2025 — an annualized return of 93.1%.
Track record
1 measurable tenure in the pay-versus-performance disclosure window. Best annualized TSR: 93.1%/yr at CTMX ( FY2022–FY2025). See the CEO track-record ranking for context.